- Home
- NMIH vs NAMS Comparison
NMIH vs NAMS Comparison
Compare NMIH & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NMIH | NAMS |
|---|---|---|
| Founded | 2011 | 2019 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 3.1B |
| IPO Year | 2013 | N/A |
Fundamental Metrics
Financial Performance| Metric | NMIH | NAMS |
|---|---|---|
| Price | $37.51 | $35.29 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 10 |
| Target Price | $41.20 | ★ $45.80 |
| AVG Volume (30 Days) | 408.3K | ★ 1.1M |
| Earning Date | 11-04-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 9.56 | N/A |
| EPS | ★ 4.79 | N/A |
| Revenue | ★ $692,208,000.00 | $35,243,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.79 | N/A |
| P/E Ratio | $7.85 | ★ N/A |
| Revenue Growth | ★ 8.86 | 4.91 |
| 52 Week Low | $31.90 | $14.06 |
| 52 Week High | $43.20 | $42.00 |
Technical Indicators
Market Signals| Indicator | NMIH | NAMS |
|---|---|---|
| Relative Strength Index (RSI) | 49.45 | 41.95 |
| Support Level | $37.91 | $34.52 |
| Resistance Level | $38.90 | $42.00 |
| Average True Range (ATR) | 0.70 | 2.02 |
| MACD | -0.00 | -0.66 |
| Stochastic Oscillator | 41.45 | 9.69 |
Price Performance
Historical ComparisonAbout NMIH NMI Holdings Inc.
NMI Holdings Inc through its subsidiaries provides private mortgage guaranty insurance. The company offers mortgage insurance, reinsurance on loans, and outsourced loan review services to mortgage loan originators. It serves national and regional mortgage banks, money center banks, credit unions, community banks, builder-owned mortgage lenders, Internet-sourced lenders, and other non-bank lenders. It protects lenders and investors from default-related losses on a portion of the unpaid principal balance of a covered mortgage.
About NAMS NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.